Bradley L. Campbell is the President and Chief Executive Officer of Amicus Therapeutics (NASDAQ: FOLD) and is also a member of the Board of Directors. He has over 20 years of experience in the Orphan Drug industry. Bradley joined Amicus in 2006 and has held various senior and executive roles throughout his tenure at the company, including Vice President of Business Planning, Senior Vice President of Business Operations, Chief Business Officer, and most recently serving as President and Chief Operating Officer from 2015 to 2022. Mr. Campbell built and led the global organization responsible for the commercialization of Galafold® and among his various roles has overseen the Technical Operations, Patient Advocacy, Market Access, Program Management, Clinical Operations, and Regulatory Affairs functions.